论文部分内容阅读
美军在小口径武器弹药中广泛采用双基球形药为主要发射药已有二十多年历史。例如从五十年代初期起,在20毫米弹上采用了制式WC870型球形药,在7.62毫米弹上采用了WC846型球形药,与当时传统的用二硝基甲苯钝感的压伸单基药相比,采用球形药的优点之一,是延长了身管寿命,因为它的绝热火焰温度较低。六十年代上半期,生产小口径武器用火药的陆军弗兰克福兵工厂与湖域陆军弹药厂合作,开始发展一种后来定名为X2048型的球形药,即将20毫米弹用制式WC870型球形药(含约80%硝化棉、约10%硝化甘油、5-7%苯二甲酸二丁酯、约1%二苯胺、微量无机添加剂如除铜剂二氧化锡、消焰剂硝酸钾和中和
The U.S. military has widely adopted double-base spherical drugs as the main propellant in small-caliber weapons and ammunition for more than 20 years. For example, from the early 1950s, a standard WC870 spherical drug was used on a 20 mm bomb, a WC846 spherical drug was used on a 7.62 mm bomb, compared with the traditional single base dinitronized with dinitrotoluene In contrast, one of the advantages of using spherical drugs is to extend the life of the barrel because of its lower adiabatic flame temperature. In the first half of the 1960s, the Army Frank Arsenal, which manufactures small-caliber weapons with gunpowder, collaborated with Lakes Field Army Ammunition to develop a spherical drug, later named X2048, about 20 millimeters of ballistic WC870 80% nitrocellulose, about 10% nitroglycerin, 5-7% dibutyl phthalate, about 1% diphenylamine, trace inorganic additives such as copper removing agent tin dioxide, flame retardant potassium nitrate and neutralizing